Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
An open-label, single-arm, single-center Phase II study to evaluate the safety and activity
of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA